JLE

European Journal of Dermatology

MENU

A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting Volume 33, issue 1, January-February 2023

  • [1] Dogra S, Mahajan R. Psoriasis: epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7:471-80.
  • [2] Global report on PSORIASIS. 2016. World Health Organization. Available at: https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis;jsessionid=54912784D28C9F36ECCD45471AC5775B?sequence=1[accessed 9 November 2020] [Epub ahead of print].
  • [3] Psoriasis statistics. 2020. National Psoariasis Foundation. Available at: https://www.psoriasis.org/psoriasis-statistics/[accessed 9 November 2020] [Epub ahead of print].
  • [4] Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016;6:121-9.
  • [5] Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:205-12.
  • [6] Megna M, Napolitano N, Balato A. Psoriasis in children: A review. Curr Pediatr Rev. 2015;11:10-26.
  • [7] Menter A, Strober BE, Kaplan DH. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
  • [8] Menter A, Cordoro KM, Davis DMR. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161-201.
  • [9] Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33:679-707.
  • [10] Wilkinson N, Jackson G, Gardner-Medwin J. Biologic therapies for juvenile arthritis. Arch Dis Child. 2003;88:186-91.
  • [11] Lovell DJ, Reiff A, Jones OY. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987-94.
  • [12] Lovell DJ, Reiff A, Ilowite NT. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496-504.
  • [13] Assessment report for Enbrel. 2011. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/variation-report/enbrel-h-c-262-ii-134-epar-assessment-report-variation_en.pdf[accessed 9 November 2020] [Epub ahead of print].
  • [14] Committee for Medicinal Products for Human use (CHMP) summary of opinion (post authorisation) for Enbrel. 2011. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enbrel_en-0.pdf[accessed 9 November 2020] [Epub ahead of print].
  • [15] Committee for Medicinal Products for Human use (CHMP) Post-authorisation summary of positive opinion for Enbrel. 2008. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-enbrel-20-november-2008_en.pdf[accessed 9 November 2020] [Epub ahead of print].
  • [16] Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int. 2011;31:327-37.
  • [17] Prescribing information for Enbrel. . . Available at: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/enbrel/enbrel_pi.pdf[accessed 9 November 2020] [Epub ahead of print].
  • [18] Menter A, Korman NJ, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137-74.
  • [19] Paller AS, Siegfried EC, Pariser DM. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74:280-7. e1-3.
  • [20] Di Lernia V, Guarneri C, Stingeni L. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2018;29:217-9.
  • [21] Paller AS, Siegfried EC, Langley RG. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-51.
  • [22] Constantin T, Foeldvari I, Vojinovic J. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43:816-24.
  • [23] Thaçi D, Papp K, Marcoux D. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181:1177-89.
  • [24] Philipp S, Menter A, Nikkels AF. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (>/= 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183:664-72.
  • [25] Bodemer C, Kaszuba A, Kingo K. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35:938-47.
  • [26] Paller AS, Seyger MMB, Alejandro Magariños G. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183:231-41.
  • [27] Bronckers I, Seyger MMB, West DP. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153:1147-57.
  • [28] Leonardi C, Strober B, Gottlieb AB. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9:928-37.